Lenalidomide is a potent immunomodulatory agent being used increasingly for treatment of hematologic malignancies including multiple myeloma and myelodysplasia. The common toxicities of lenalidomide, including dose-limiting myelosuppression, are well described. However, the immunomodulatory properties of lenalidomide may give rise to unexpected autoimmune complications. Herein, we describe a case of immune thrombocytopenic purpura (ITP) associated with use of lenalidomide.
CITATION STYLE
Herold, C. I., Gasparetto, C., & Arepally, G. M. (2011). Lenalidomide-Associated ITP. Case Reports in Hematology, 2011, 1–4. https://doi.org/10.1155/2011/638020
Mendeley helps you to discover research relevant for your work.